FTI 277

a ras CAAX (C - Cys; A - aliphatic amino acid; X - Ser or Met) peptidomimetic; inhibits farnesyltransferase; blocks Ras oncogenic signaling by accumulating Ras/Raf complexes in the cytoplasm; structure given in first source

Also Known As:

Networked: 41 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hamilton, A D: 4 articles (02/2003 - 01/2000)
2.	Kaneki, Masao: 3 articles (01/2021 - 12/2011)
3.	Sebti, S M: 3 articles (02/2003 - 01/2000)
4.	Nakazawa, Harumasa: 2 articles (01/2021 - 01/2015)
5.	Fischman, Alan J: 2 articles (01/2015 - 12/2011)
6.	Tompkins, Ronald G: 2 articles (01/2015 - 12/2011)
7.	Yamada, Marina: 2 articles (01/2015 - 12/2011)
8.	Yu, Yong-Ming: 2 articles (01/2015 - 12/2011)
9.	Hisa, Hiroaki: 2 articles (04/2014 - 02/2008)
10.	Mutoh, Junpei: 2 articles (04/2014 - 02/2008)

Related Diseases

1.	Sepsis (Septicemia) 12/01/2011 - "FTI-277 reverted to or mitigated sepsis-induced apoptosis in spleen and thymus, increased splenic CD4(+)Foxp3(+) Tregs, and suppressed IFN-γ secretion and proliferation of splenocytes in response to anti-CD3+CD28 antibodies in mice. " 01/01/2021 - "Farnesyltransferase inhibitor, FTI-277, prevented sepsis-induced morphological aberrations of the mitochondria, and blocked the increased plasma mtDNA levels along with improved survival. "
2.	Colorectal Neoplasms (Colorectal Cancer) 07/01/2007 - "In our present study, we found that FTI-277 (a farnesyltransferase inhibitor), U0126 [an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)], and 17-allylamino-17-demethoxygeldanamycin (an inhibitor of heat shock protein 90) reduced the endogenous expression levels of P-gp in the human colorectal cancer cells, HCT-15 and SW620-14. "
3.	Liver Neoplasms (Liver Cancer) 01/01/2003 - "In the present study, we investigated the effects of the farnesyltransferase inhibitor FTI-277 on two human liver cancer cell lines, HepG2 and Huh7. " 01/01/2003 - "Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines."
4.	Insulin Resistance 01/01/2015 - "Our data demonstrate that burn increased FTase expression and protein farnesylation along with insulin resistance, metabolic alterations and inflammatory response in mouse skeletal muscle, all of which were prevented by FTI-277 treatment. " 01/01/2015 - "To study a role of farnesylation in burn-induced metabolic aberration, we examined the effects of farnesyltransferase (FTase) inhibitor, FTI-277, on burn-induced insulin resistance and metabolic alterations in mouse skeletal muscle. "
5.	Hepatocellular Carcinoma (Hepatoma) 06/01/2018 - "Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study." 06/01/2018 - "Treatment of hepatocellular carcinoma (HCC) cell line with FTI-277 alone showed cell death in a time and dose dependent manner while in combination with alendronate, a synergistic apoptotic effect at 24 h was observed. "

Related Drugs and Biologics

1.	Farnesyltranstransferase (Farnesyltransferase)
2.	Mitochondrial DNA (mtDNA)
3.	GGTI 298
4.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
5.	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)
6.	Mitogen-Activated Protein Kinases
7.	Alendronate (Alendronate Sodium)
8.	Heat-Shock Proteins (Heat-Shock Protein)
9.	GGTI 286
10.	U 0126 (UO 126)